rxstatShortages › Ranitidine

Ranitidine (Zantac, Acid Reducer) shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Some Ranitidine products are in shortage in Canada (12 of 36 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.

An acid-reducing medication (H2 blocker) used to treat heartburn, acid reflux and ulcers.

Products affected
12 / 36
In shortage since
Mar 10, 2017
Reports on file
127
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Book a pharmacist appointment
Need your prescription switched?
If your product stays unavailable, an online doctor can assess your situation and prescribe an alternative.
See a doctor online

Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.

Shortage history

2023 2024 2025 2026

Shortage history (red bands = periods in shortage).

Reports by product

The DIN is printed on your prescription label.

Active shortage
PMS-RANITIDINE 300 MG
300MG · TABLET · PHARMASCIENCE INC
DIN 02242454 · since Oct 23, 2019, no end estimate · Disruption of the manufacture of the drug.
Active shortage
PMS-RANITIDINE 150 MG
150MG · TABLET · PHARMASCIENCE INC
DIN 02242453 · since Oct 23, 2019, no end estimate · Disruption of the manufacture of the drug.
Active shortage
PMS-RANITIDINE 150 MG
150MG · TABLET · PHARMASCIENCE INC
DIN 02242453 · since Oct 23, 2019, no end estimate · Disruption of the manufacture of the drug.
Active shortage
PMS-RANITIDINE 150 MG
150MG · TABLET · PHARMASCIENCE INC
DIN 02242453 · since Oct 23, 2019, no end estimate · Disruption of the manufacture of the drug.
Active shortage
JAMP-RANITIDINE
300MG · TABLET · JAMP PHARMA CORPORATION
DIN 02463725 · since Oct 7, 2019, est. end Dec 30, 2022 · Disruption of the manufacture of the drug.
Active shortage
JAMP-RANITIDINE
150MG · TABLET · JAMP PHARMA CORPORATION
DIN 02463717 · since Oct 7, 2019, est. end Dec 30, 2022 · Disruption of the manufacture of the drug.
Active shortage
JAMP-RANITIDINE
150MG · TABLET · JAMP PHARMA CORPORATION
DIN 02463717 · since Oct 7, 2019, est. end Dec 30, 2022 · Disruption of the manufacture of the drug.
Active shortage
APO-RANITIDINE
15MG · SOLUTION · APOTEX INC
DIN 02280833 · since Sep 17, 2019, no end estimate · Disruption of the manufacture of the drug.
Active shortage
APO-RANITIDINE TABLET 300MG
300MG · TABLET · APOTEX INC
DIN 00733067 · since Sep 17, 2019, no end estimate · Disruption of the manufacture of the drug.
Active shortage
APO-RANITIDINE TABLET 150MG
150MG · TABLET · APOTEX INC
DIN 00733059 · since Sep 17, 2019, no end estimate · Disruption of the manufacture of the drug.
Active shortage
RANITIDINE
300MG · TABLET · SANIS HEALTH INC
DIN 02353024 · since Sep 16, 2019, no end estimate · Requirements related to complying with good manufacturing practices.
Active shortage
RANITIDINE
150MG · TABLET · SANIS HEALTH INC
DIN 02353016 · since Sep 16, 2019, no end estimate · Requirements related to complying with good manufacturing practices.

Showing 12 of 60 reports. All reports are on file with Health Canada.

What's happening

Ranitidine is currently affected by 12 active shortage reports filed with Health Canada by PHARMASCIENCE INC, JAMP PHARMA CORPORATION, APOTEX INC, SANIS HEALTH INC and 1 others.

The reported causes are: disruption of the manufacture of the drug; requirements related to complying with good manufacturing practices; health canada imposed distribution restriction. Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Ranitidine is classified under “DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD)” (ATC A02BA).

Recent changes

Common questions

What is Ranitidine used for?

An acid-reducing medication (H2 blocker) used to treat heartburn, acid reflux and ulcers.

When will Ranitidine be back in stock in Canada?

Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.

Why is Ranitidine in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Possible alternatives in the same class (drugs for peptic ulcer and gastroesophageal reflux disease (gerd))

Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.